Indeed, both genetic ablation of osteopontin has been shown to reduce dystrophic pathologies in mdx muscles, and subsequently anti-osteopontin compounds are being pursued for DMD therapies due to their ability to shift macrophages to a pro-regenerative phenotype [45,56]. Here, SPP1 is linked to Duchenne muscular dystrophy.